Cellular Biomedicine Acquires CAR-T Technology from China Hospital

Cellular Biomedicine Group, a China-US cell therapy company, acquired CAR-T cancer immunotherapy technology from the Chinese PLA General Hospital of Beijing. The two groups will form a partnership for further development of the products in China. The PLA Hospital has already conducted early clinical trials of the technology on CD19-positive acute lymphoblastic leukemia, CD20-positive lymphoma, CD30-positive Hodgkin's lymphoma and EGFR-HER1-positive advanced lung cancer. The data from the Phase I and II trials is included in the deal. More details.... Stock Symbol: (NSDQ: CBMG) Share this with colleagues: // //